Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation

Thrombosis and Haemostasis

Volumn 116, Issue 3, 2016, Pages 544-553

  Kittelson, John M ^a   Steg, Philippe Gabriel ^b,c,d,e   Halperin, Jonathan L ^f   Goldenberg, Neil A ^g,h   Schulman, Sam ⁱ   Spyropoulos, Alex C ^j   Kessler, Craig M ^k   Turpie, Alexander G G ⁱ   Cutler, Neal R ^l   Hiatt, William R ^m  

^a Global Health and Health Disparities   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^k GEORGETOWN UNIVERSITY   (United States)

^l Worldwide Clinical Trials   (United States)

^m UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Clinical trial; Meta analysis; Net clinical benefit; Noninferiority

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; COMPLICATION; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE III AS TOPIC; HEMORRHAGE; HUMANS; MODELS, STATISTICAL; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLES; THROMBOEMBOLISM; WARFARIN;

EID: 84989165979     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-12-1000     Document Type: Article

References (26)

1. Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. Br Med J 2013; 347: f5133.
2. Chatterjee S, Sardar P, Biondi-Zoccai G, et al. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. J Am Med Assoc Neurol 2013; 70: 1486–1490.
3. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381–2391.
4. Pancholy SB, Sharma PS, Pancholy DS, et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113: 485–490.
5. van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and metaanalysis. J Thromb Haemost 2014; 12: 320–328.
6. Chai-Adisaksopha C, Crowther M, Isayama T, et al. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood 2014; 124: 2450–2458.
7. Gangireddy SR, Halperin JL, Fuster V, et al. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. Eur Heart J 2012; 33: 2700–2708.
8. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297–305.
9. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
12. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
13. Kittelson JM, Spyropoulos AC, Halperin JL, et al. Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. J Thromb Haemost 2013; 11: 1443–1448.
14. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635–641.
15. Investigators RAS. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340–347 e1.
16. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805–810 e1–2.
17. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
18. Cordoba G, Schwartz L, Woloshin S, et al. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. Br Med J 2010; 341: c3920.
19. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics Med 2002; 21: 589–624.
20. Hemming K, Hutton JL, Maguire MG, et al. Meta-regression with partial information on summary trial or patient characteristics. Statistics Med 2010; 29: 1312–1324.
21. Arends LR, Voko Z, Stijnen T. Combining multiple outcome measures in a meta-analysis: an application. Statistics Med 2003; 22: 1335–1353.
22. Thall PFCS. Treatment comparisons based on two-dimensional safety adn efficacy alternatives in oncology trials. Biometrics 1999; 55: 746–753.
23. Draper NSN. Applied Regression Analysis, 2nd edition (pp 94–95). New York: John Wiley & Sons; 1981.
24. G A. Elementary Bayesian Statistics: Edward Algar Publishing; 1997. 480 p.
25. Tripputi M. Use of Mediation in Designing Clinical Trials with two Primary Endpoints. PhD Dissertation, George Washington University. 2009.
26. Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Statistics Med 2010; 29: 2769–2780.